Dr. Gangothri Selvarajan

Dr. Gangothri Selvarajan, MD, DM Associate Professor, Medical Oncology Cancer Institute (WIA), Chennai, India Dr. Gangothri Selvarajan is a highly qualified Medical Oncologist with advanced dual-specialty training in Radiation Oncology and Medical Oncology, currently serving as Associate Professor of Medical Oncology at Cancer Institute (WIA), Chennai, one of India's premier tertiary cancer care and academic institutions . ________________________________________ Academic Qualifications and Specialist Training Dr. Selvarajan completed her MBBS from Chengalpattu Medical College, followed by an MD in Radiation Oncology from Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, and subsequently obtained her DM in Medical Oncology from Madras Medical College, Chennai—one of the highest superspecialty qualifications in oncology in India. She also holds the Specialty Certificate in Medical Oncology (MRCP-SCE) from the Federation of the Royal Colleges of Physicians, United Kingdom, and has successfully cleared the European Society for Medical Oncology (ESMO) Examination, reflecting adherence to international standards of oncology practice. ________________________________________ Clinical Roles and Patient Care At Cancer Institute (WIA), Dr. Gangothri Selvarajan is actively involved in: Her primary clinical interests include breast cancer, gastrointestinal malignancies, gynecologic cancers, thoracic oncology, and precision oncology, with emphasis on individualized treatment strategies and real-world outcome optimization . ________________________________________ Research Experience and Clinical Trial Leadership Dr. Selvarajan has extensive experience in clinical research and investigator-initiated trials, serving as Principal Investigator or Co-Primary Investigator in several national and multicentric randomized controlled trials. Key leadership roles include: A DHR-funded randomized study comparing neoadjuvant versus adjuvant chemotherapy in resectable gastric adenocarcinoma. Evaluating organ preservation strategies in rectal cancer. Conducted in patients with HER2-positive metastatic breast cancer. She has also contributed as Co-Investigator in multiple Phase II and Phase III trials in breast cancer, lymphoma, triple-negative breast cancer, metastatic disease, and supportive oncology. Abstracts from these studies have been presented at ASCO, ESMO, ESTRO, ASH, and KINGCA scientific meetings . ________________________________________ Publications and Academic Contributions Dr. Gangothri Selvarajan has authored and co-authored numerous peer-reviewed publications indexed in PubMed, encompassing: Her scholarly work contributes significantly to institutional academic output and supports research metrics required for accreditation and ranking . ________________________________________ Awards, Gold Medals, and Recognitions Her academic excellence has been recognized through multiple honors, including: These recognitions reflect sustained excellence in academic oncology, clinical research, and mentorship . ________________________________________ International Fellowships and Advanced Training Dr. Gangothri Selvarajan has completed advanced international training and fellowships at: She has formal training in next-generation sequencing (NGS), bioinformatics, proteomics, and translational oncology, strengthening institutional precision medicine capabilities. ________________________________________ Professional Memberships and Academic Service Dr. Selvarajan is an active member of: She also serves as a peer reviewer for national and international oncology journals and regularly contributes to continuing medical education (CME) programs. ________________________________________ Professional Outlook Dr. Gangothri Selvarajan is committed to delivering ethical, evidence-based, and patient-centered cancer care, while advancing clinical research, academic oncology, and structured oncology training. Her work integrates multidisciplinary care, clinical trials, and precision oncology to enhance patient outcomes and institutional excellence. ________________________________________